SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer
Posted innews Oncology Radiology

SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer

The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall survival benefit except possibly for pT3N0 disease.
ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction
Posted inGastroenterology news Oncology

ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction

A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred palliative therapy when expertise is available.
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction
Posted inGastroenterology news Oncology

CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction

Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but are less penetrant than CDH1 mutations; proposes simplified testing ('Porto' criteria) and clinical implications.
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Posted innews Oncology

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and suggests clinical benefit — including signals versus historical second‑line FOLFOX — warranting randomized validation.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Posted inGastroenterology news Oncology

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Posted inGastroenterology news Oncology Transplantation

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI washout, and younger recipient age were independent predictors.
Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra
Posted innews Oncology Urology

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematologic grade ≥3 adverse events were uncommon.
Vorasidenib Slows Tumour Growth and Reduces Seizures in IDH‑Mutant Grade 2 Glioma — Robust PFS and Preserved Cognition in the INDIGO Phase 3 Trial
Posted inNeurology news Oncology

Vorasidenib Slows Tumour Growth and Reduces Seizures in IDH‑Mutant Grade 2 Glioma — Robust PFS and Preserved Cognition in the INDIGO Phase 3 Trial

In the INDIGO phase 3 trial, vorasidenib markedly prolonged progression‑free survival and time to next intervention, reduced volumetric tumour growth and seizure burden, and preserved quality of life and neurocognitive function in patients with grade 2 IDH1/2‑mutant diffuse glioma after surgery.